Related Experiment Videos

Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy

Rossana Roncato¹, Erika Cecchin¹, Giuseppe Toffoli¹

¹Experimental & Clinical Pharmacology, Centro Di Riferimento Oncologico - National Cancer Center, Aviano (PN), Italy.

Pharmacogenomics

|February 15, 2018

Abstract

No abstract available in PubMed .

Keywords:

DRG cost of toxicity management direct medical costs personalized medicine pharmacoeconomy pharmacogenomics real-world data reimbursement strategy

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Clinical Validity of Imatinib Therapeutic Drug Monitoring in a Real-World Italian Cohort of Gastrointestinal Stromal Tumors and the Role of Patients' Sex.

Pharmaceutics·2026

Identification of a large DPYD gene deletion undetected by standard genotyping in a patient with severe capecitabine-related toxicity: a case report.

Frontiers in pharmacology·2026

Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence.

Pharmacology research & perspectives·2026

Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy.

Chemotherapy·2026

DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity.

International journal of cancer·2026

PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal adenocarcinoma.

Nanomedicine (London, England)·2026

See all related articles